6NKH | pdb_00006nkh

Structure of MalC Reductase/Diels-Alderase from Malbranchea aurantiaca

  • Classification: OXIDOREDUCTASE
  • Organism(s): Malbranchea aurantiaca
  • Expression System: Escherichia coli
  • Mutation(s): No 

  • Deposited: 2019-01-07 Released: 2019-10-09 
  • Deposition Author(s): Dan, Q., Newmister, S.A., Smith, J.L., Sherman, D.H.
  • Funding Organization(s): National Institutes of Health/National Cancer Institute (NIH/NCI), National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS), National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Disease (NIH/NIDDK)

Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free: 
    0.199 (Depositor), 0.197 (DCC) 
  • R-Value Work: 
    0.166 (Depositor), 0.164 (DCC) 
  • R-Value Observed: 
    0.170 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 6NKH

This is version 1.3 of the entry. See complete history

Literature

Fungal indole alkaloid biogenesis through evolution of a bifunctional reductase/Diels-Alderase.

Dan, Q.Newmister, S.A.Klas, K.R.Fraley, A.E.McAfoos, T.J.Somoza, A.D.Sunderhaus, J.D.Ye, Y.Shende, V.V.Yu, F.Sanders, J.N.Brown, W.C.Zhao, L.Paton, R.S.Houk, K.N.Smith, J.L.Sherman, D.H.Williams, R.M.

(2019) Nat Chem 11: 972-980

  • DOI: https://doi.org/10.1038/s41557-019-0326-6
  • Primary Citation Related Structures: 
    6NKH, 6NKI, 6NKK, 6NKM

  • PubMed Abstract: 

    Prenylated indole alkaloids such as the calmodulin-inhibitory malbrancheamides and anthelmintic paraherquamides possess great structural diversity and pharmaceutical utility. Here, we report complete elucidation of the malbrancheamide biosynthetic pathway accomplished through complementary approaches. These include a biomimetic total synthesis to access the natural alkaloid and biosynthetic intermediates in racemic form and in vitro enzymatic reconstitution to provide access to the natural antipode (+)-malbrancheamide. Reductive cleavage of an L-Pro-L-Trp dipeptide from the MalG non-ribosomal peptide synthetase (NRPS) followed by reverse prenylation and a cascade of post-NRPS reactions culminates in an intramolecular [4+2] hetero-Diels-Alder (IMDA) cyclization to furnish the bicyclo[2.2.2]diazaoctane scaffold. Enzymatic assembly of optically pure (+)-premalbrancheamide involves an unexpected zwitterionic intermediate where MalC catalyses enantioselective cycloaddition as a bifunctional NADPH-dependent reductase/Diels-Alderase. The crystal structures of substrate and product complexes together with site-directed mutagenesis and molecular dynamics simulations demonstrate how MalC and PhqE (its homologue from the paraherquamide pathway) catalyse diastereo- and enantioselective cyclization in the construction of this important class of secondary metabolites.


  • Organizational Affiliation
    • Life Sciences Institute, University of Michigan, Ann Arbor, MI, USA.

Macromolecule Content 

  • Total Structure Weight: 113.06 kDa 
  • Atom Count: 8,475 
  • Modeled Residue Count: 1,033 
  • Deposited Residue Count: 1,056 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Short chain dehydrogenase
A, B, C, D
264Malbranchea aurantiacaMutation(s): 0 
Gene Names: malC
EC: 1.1
UniProt
Find proteins for L0E4F8 (Malbranchea aurantiaca)
Explore L0E4F8 
Go to UniProtKB:  L0E4F8
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupL0E4F8
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.60 Å
  • R-Value Free:  0.199 (Depositor), 0.197 (DCC) 
  • R-Value Work:  0.166 (Depositor), 0.164 (DCC) 
  • R-Value Observed: 0.170 (Depositor) 
Space Group: P 42
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 79.368α = 90
b = 79.368β = 90
c = 133.586γ = 90
Software Package:
Software NamePurpose
PHENIXrefinement
XDSdata scaling
PHENIXphasing

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Cancer Institute (NIH/NCI)United StatesR01CA070375
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesR35GM118101
National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Disease (NIH/NIDDK)United StatesR01DK042303

Revision History  (Full details and data files)

  • Version 1.0: 2019-10-09
    Type: Initial release
  • Version 1.1: 2019-11-06
    Changes: Data collection, Database references
  • Version 1.2: 2019-12-04
    Changes: Author supporting evidence
  • Version 1.3: 2024-03-13
    Changes: Data collection, Database references